Trial Profile
CARMELINA: A Multicenter, International, Randomized, Parallel Group, Double-blind, Placebo-controlled, Cardiovascular Safety and Renal Microvascular Outcome Study With Linagliptin, 5 mg Once Daily in Patients With Type 2 Diabetes Mellitus at High Vascular Risk
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 15 Dec 2022
Price :
$35
*
At a glance
- Drugs Linagliptin (Primary)
- Indications Cardiovascular disorders; Type 2 diabetes mellitus
- Focus Adverse reactions
- Acronyms CARMELINA
- Sponsors Boehringer Ingelheim
- 07 Nov 2022 Results assessing the associations between hypoglycemia and cardiovascular outcomes from the CARMELINA and CAROLINA trials of the linagliptin, an antihyperglycemic medication, presented at the American Heart Association Scientific Sessions 2022.
- 16 Jun 2020 Results of pooled analysis from linagliptin arm from CARMELINA and CAROLINA and placebo arm from EMPA-REG OUTCOME studies presented at the 80th Annual Scientific Sessions of the American Diabetes Association
- 22 May 2020 Results assessing secondary analyses of cardiovascular (CV) and kidney outcomes across baseline estimated glomerular filtration rate (eGFR) categories published in the Diabetes Care